Sonnet BioTherapeutics Provides Fiscal Year 2022 Business and Financial Update

Sonnet BioTherapeutics Provides Fiscal Year 2022 Business and Financial Update

PRINCETON, NJ / ACCESSWIRE / December 15, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (“Sonnet” or the “Company”), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the fiscal year ended September 30th, 2022 and provided a business update. Pankaj Mohan, Ph.D., Founder and CEO commented, “This was a defining…

Read More